奥沙利铂对原发性肝癌细胞系HUH-7的抗肿瘤效果评价

目的：探讨奥沙利铂对原发性肝癌细胞系HUH-7是否会产生作用和影响,根据其对抗肿瘤的效果决定是否能够应用于对肝癌细胞的临床治疗。方法把中科院2012年3月—2014年4月的肝癌细胞作为该试验的研究对象,用流式细胞仪器对癌细胞的分布周期和死亡状况进行分析,运用MTT法测试不同浓度和不同的作用时间的奥沙利铂对肝癌细胞增长繁殖的抑制效果。通过多次试验,得出最终结论。结果经过48 h作用后,癌细胞死亡率达到了11.8%,可见奥沙利铂对于肝癌细胞的繁衍增长有着很强的抑制功效,并且呈现出计量和时间的依赖性。结论奥沙利铂对原生性肝癌细胞系HUH-7的抗瘤效果明显,它可以抑制肝癌细胞繁殖,使细胞周期停留在S期和G2PM期之间,进而使癌细胞死亡。但是其具体的运行机制还有待研究,因而奥沙利铂能否应用于临床治疗还不能盖棺定论。     

温哥华量表在90Sr治疗瘢痕疙瘩中的应用

目的 在瘢痕疙瘩患者进行90Sr同位素敷贴治疗前,按照温哥华瘢痕量表进行评分,推断治疗效果,合理选择适应症.方法 选取2008年1月至2013年1月在本院皮肤科及外科门诊确诊的瘢痕疙瘩患者105例,按照温哥华瘢痕量表根据色泽、厚度、血管分布、柔软度进行评分,分为两组(A组0～8分,B组9～15分),采用90Sr同位素敷贴治疗,治疗后随访6 ～12个月,进行疗效评价.结果 在131例瘢痕疙瘩患者中,痊愈率48.09％;好转率51.91％;总有效率100％.其中A组剂量30.12±3.15Gy,痊愈率62.69％,不良反应发生率16.42％.B组剂量44.16±5.56Gy,痊愈率32.81％,不良反应发生率48.48％.经spssl6.0统计学软件处理,差异有统计学意义.结论 在瘢痕疙瘩患者进行90Sr同位素敷贴治疗前,按照温哥华瘢痕量表进行评分,根据量表评分来选择合适患者治疗,是一种简单、有效且较为准确的方法.     

实施一体化护理管理对供应室医疗器械护理风险管理的实践与思考

消毒供应室主要针对医院内部不同医疗器械的消毒,医疗器械有的来源于临床科室,有的来源于手术室,统一规范的一体化管理有助于减少医疗器械引发的护理不良事件。本研究旨在采用规范化的管理方式降低因医疗器械引发的医院感染,提高医护人员满意度及工作效率。     

PI3K信号通路在呼吸系统疾病中的研究进展

在过去20多年中,科学家们对磷脂酰肌醇3激酶(phosphoinositide 3-kinase,PI3K)信号通路的研究取得了长足进步.不仅发现了许多特异性的PI3K信号通路抑制剂,而且还证明了许多抑制剂 可能对呼吸系统疾病的治疗有良好作用.在本文中,我们通过简要介绍PI3K信号的各种异构体,重点探讨利用这些PI3K异构体作为药物靶点的分子来治疗呼吸系统疾病的现状和前景.例如,科学家们已经能够通过抑制PI3Kα治疗肺癌,抑制PI3Kβ治疗肺动脉高压,而PI3Kδ以及PI3 Kγ在气道炎症性疾病中的研究也有突破.最后,我们还将简要分析PI3K抑制剂治疗呼吸系统相关疾病的前景和展望.     

β-榄香烯治疗结直肠癌作用机制研究进展

结直肠癌具有较高的发病率和病死率,药物治疗可延长生存期,但会出现不同程度的耐药。β-榄香烯是从温郁金中提取的活性成分,具有广谱的抗肿瘤活性,可抑制肿瘤细胞生长和增殖、诱导肿瘤细胞凋亡、抑制肿瘤细胞侵袭和转移、逆转肿瘤药物耐药、联合化疗增效减毒、同步放疗增敏、改善免疫功能。综述了β-榄香烯治疗结直肠癌的作用机制研究进展,以期为β-榄香烯临床治疗结直肠癌提供参考。     

基于中性粒细胞胞外诱捕网探讨白及修复溃疡性结肠炎大鼠肠 黏膜屏障的作用及机制

目的 基于中性粒细胞胞外诱捕网(NETs)探讨白及对溃疡性结肠炎(UC)大鼠肠黏膜屏障的修复作用及机制。方法 将48只SD大鼠随机分为正常组、模型组、柳氮磺胺吡啶组(0.3 g·kg^-1)及白及低、中、高剂量组(0.3、0.6、1.2 g·kg^-1),每组8只。采用2,4,6-三硝基苯磺酸(TNBS)-乙醇灌肠法复制UC大鼠模型,造模成功后按照设定剂量灌胃给药,每日1次,连续灌胃给药21 d。在给药干预的第1、11、21天进行疾病活动指数(DAI)评分;采用HE染色法观察大鼠结肠组织病理变化;ELISA法检测大鼠血清中肿瘤坏死因子α(TNF-α)和白细胞介素1β(IL-1β)含量;Western Blot法及免疫组化法检测大鼠结肠组织中NETs相关蛋白髓过氧化物酶(MPO)、中性粒细胞弹性蛋白酶(NE)、血管内皮生长因子(VEGF)以及紧密连接(TJs)相关蛋白封闭蛋白2(CLDN2)、闭锁小带蛋白1(ZO-1)的表达水平。结果 与正常组比较,模型组大鼠DAI明显升高(P<0.05);结肠组织黏膜层出现大面积变性坏死且肠腺结构消失...     

Relationship of body fat and left ventricular hypertrophy with the risk of all-cause death in patients with coronary artery disease

BACKGROUNDLeft ventricular hypertrophy (LVH) is prevalent in obese individuals. Besides, both of LVH and obesity is associated with subclinical LV dysfunction. The study aims to investigate the interplay between body fat and LVH in relation to all-cause death in patients with coronary artery disease (CAD).METHODSIn this retrospective cohort study, a total of 2243 patients with angiographically proven CAD were included. Body fat and LV mass were calculated using established formulas. Patients were grouped according to body fat percentage and presence or absence of LVH. Cox-proportional hazard models were used to observe the interaction effect of body fat and LVH on all-cause death.RESULTSOf 2243 patients enrolled, 560 (25%) had a higher body fat percentage, and 1045 (46.6%) had LVH. After a median follow-up of 2.2 years, the cumulative mortality rate was 8.2% in the group with higher body fat and LVH, 2.5% in those with lower body fat and no LVH, 5.4% in those with higher body fat and no LVH, and 7.8% in those with lower body fat and LVH (log-rank P < 0.001). There was a statistically significant interaction between body fat percentage and LVH ( P interaction was 0.003). After correcting for confounding factors, patients with higher body fat and LVH had the highest risk of all-cause death (HR = 3.49, 95% CI: 1.40–8.69, P = 0.007) compared with those with lower body fat and no LVH; in contrast, patients with higher body fat and no LVH had no statistically significant difference in risk of death compared with those with lower body fat and no LVH (HR = 2.03, 95% CI: 0.70–5.92, P = 0.195). CONCLUSIONA higher body fat percentage was associated with a different risk of all-cause death in patients with CAD, stratified by coexistence of LVH or not. Higher body fat was significantly associated with a greater risk of mortality among patients with LVH but not among those without LVH.

Last 40 years have witnessed sharply rise of obesity prevalence at any age and gender around the world. In the concept of obesity transition, China has been classified into stage 2, which is characterized by a significant increase of obesity prevalence in adults surpassing that among children, and a narrowing distinction between sexes.^[1] In 2012, obesity prevalence in Chinese residents aged over 18 years old is 11.9%. About 13.5% of cardiovascular deaths were attributable to high body mass index in 2017; furthermore, the direct economic burden of overweight and obesity rose to 90.768 billion yuan (RMB), which is accounted for 4.5% of total health expenditure of China in 2010.^[2] Obesity, itself or concomitant with other comorbidities, contribute to a higher risk of incident coronary artery disease (CAD).^[3] Cardiac remodeling and functional changes are also prevailing phenomena in obese individuals. A meta-analysis showed that the prevalence of left ventricular hypertrophy (LVH) in obese individuals was 56%, ranging from 20% to 85% according to different criteria of LVH.^[4] In patients with coronary artery stenosis, LVH was associated with the presence of myocardial ischemia and the extent of involvement independent of traditional cardiovascular risk factors.^[5]With in-depth research on the pathogenesis heart failure with preserved ejection fraction, increasing weight has been given to the impact of obesity and LVH on cardiovascular system.^[6] Although we are well aware of the adverse effects of body fat on cardiovascular metabolism, for patients who have been diagnosed with CAD, the role of body fat may be heterogeneous.^[7,8] In other words, for those patients, some studies have reported the phenomenon of the obesity paradox, while other studies have observed the U-shaped curve between obesity and prognosis, and some studies have not observed the relationship between obesity and better clinical endpoints.^[8,9] It is very important to clarify the association between body fat and the prognosis among patients with CAD because it will determine how to guide them on weight management. Actually, physical activity can improve the cardiopulmonary function status of patients with cardiovascular disease. Therefore, identifying which patients with obesity have a worse prognosis and need to be focused on as target population to improve management and reduce the burden of disease is worthy of further observation. Since LVH is very closely related to adipose tissue and adverse cardiovascular events, it may play an important role in the risk stratification of patients with obesity concomitant with CAD.^[10] Previous studies demonstrated that the reaction of ventricular sarcomere contractility to increased calcium stimulation was substantially depressed in severely obese patients; furthermore, LVH and obesity had a superposition effect on regional LV dysfunction.^[11,12] In this study, we investigated the interplay relationship of body fat and LVH with the risk of all-cause death in patients with CAD.     

男性对配偶围产期丧失体验的Meta整合

目的 系统整合男性对配偶围产期丧失体验的质性研究,为制订相关心理干预措施提供依据.方法 检索中国生物医学文献数据库、中国知网、PubMed、Web of Science、CINAHL、PsychINFO、Embase、Cochrane Library数据库及数据平台中有关男性对配偶围产期丧失体验的质性研究,检索时限为建...     

靶向AKT1和COX-2的RNAi抑制U251胶质瘤细胞侵袭的体外实验

目的应用RNA干扰(RNA interference,RNAi)技术敲低恶性胶质瘤细胞系U251中AKT1和COX-2表达后,在体外对细胞侵袭转移的抑制作用,初步探讨其可能的作用机制。方法构建重组腺病毒载体rAd5-A-C同时搭载靶向AKT1和COX-2的shRNA干扰序列,将其转染至恶性胶质瘤细胞系U251细胞。Realtime PCR检测RNAi后目的基因mRNA的表达水平,Western Blot检测目的基因及MMP-2、MMP-9、TIMP-2的表达情况。酶联免疫吸附试验检测转染前后分泌到细胞外的MMP-2和MMP-9的浓度变化。划痕实验和Transwell实验评价肿瘤细胞转染前后的细胞侵袭能力的变化。结果rAd5-A-C转染组AKT1和COX-2的mRNA和蛋白表达均明显抑制;MMP-2、MMP-9表达下调,TIMP-2表达则上调。ELISA检测胞外MMP-2、MMP-9浓度明显减低;划痕实验显示细胞转移运动能力明显减弱,Transwell体外侵袭实验结果显示穿过细胞数明显减低(P0.001)。结论重组腺病毒介导的RNAi技术可以序列特异性地抑制U251细胞AKT1和COX-2的表达,在体外对U251细胞侵袭转移产生明显抑制作用,可能成为恶性胶质瘤治疗的新策略。